UBC ClinResearch to Expand Global Reach in Pioneering Field
BETHESDA, Md., Sept. 10 /PRNewswire/ -- United BioSource Corporation (UBC) today announced the acquisition of an ownership interest in ClinResearch GmbH, a global leader in technology solutions and services for flexible, or adaptive, clinical trials. Headquartered in Cologne, Germany, with more than 100 employees, ClinResearch has designed and implemented 80 adaptive programs over the past seven years. ClinResearch's co-founder, Reinhard Eisebitt, is a co-developer of the leading software used by pharmaceutical companies and contract research organizations (CROs) throughout the world to support the rigorous statistical requirements of adaptive trials.
ClinResearch, which will now operate under the name UBC ClinResearch, will be a centerpiece of UBC's adaptive design clinical trial offering and will deliver a full service, global solution for pharmaceutical, biotechnology and medical device companies seeking to capitalize on the benefits of adaptive design in their clinical development strategy.
"We are thrilled to welcome ClinResearch to the UBC family," said Ethan Leder, CEO of UBC. "Having worked with the founders for several years, we know that they are an excellent fit with our culture and vision. They are innovative and science driven, and have built a world-class organization with a track record of developing and executing technology solutions that we plan to introduce aggressively to our growing base of sponsor and CRO clients."
"The interest in adaptive design is accelerating from the early adopter to the rapid growth stage. We are excited to be joining an organization with the resources to allow us to capitalize on this opportunity," noted Michael Fischer, PhD, founder of ClinResearch. Fischer added, "We are moving forward with expansion plans to fulfill demand on our global projects with UBC and anticipate growth in Cologne, as well as in our offices in Russia and the Ukraine to benefit our clients."
According to Patrick Lindsay, Executive Vice President of UBC, "ClinResearch's leadership in adaptive design is consistent with UBC's focus on innovative solutions for clinical development. Reinhard Eisebitt, ClinResearch's co-founder, is recognized by the FDA and European regulatory authorities as a thought leader in adaptive design based on the proprietary software and techniques that he helped develop. We look forward to bringing our combined strengths in this novel and quickly evolving methodology to the industry." The ClinResearch announcement is the latest in a series of transactions made since UBC raised $153 million in equity capital from a syndicate of leading private equity firms in 2003.
Since 1999, ClinResearch, GmbH, headquartered in Cologne, Germany, has been a leader in planning, conducting and reporting clinical studies for the pharmaceutical and medical device industries. For more information, visit http://www.clinresearch.com.
United BioSource Corporation (UBC) is a global pharmaceutical services organization that helps emerging and established life science companies develop and commercialize medical products. UBC specializes in offering new and innovative ways to study drugs and devices by offering expertise in science, strategy and execution.
UBC is headquartered in Bethesda, Maryland, with offices in the United States, Canada, Europe and South America. For more information, visit http://www.unitedbiosource.com or call 866-458-1096.
CONTACT: Tess Drahzal, +1 (240) 644-0420, email@example.com
|SOURCE United BioSource Corporation|
Copyright©2007 PR Newswire.
All rights reserved